When is partial nephrectomy nephron-sparing surgery (NSS) indicated in the treatment of renal masses?

Updated: Apr 01, 2019
  • Author: Reza Ghavamian, MD; Chief Editor: Bradley Fields Schwartz, DO, FACS  more...
  • Print
Answer

Synchronous bilateral tumors, tumors in a solitary kidney, and the presence of a poorly functional contralateral renal unit are generally absolute indications for nephron-sparing surgery (NSS). The latter scenario could result from the concomitant presence of unilateral renal cell carcinoma (RCC) and a contralateral kidney with disease processes (eg, chronic pyelonephritis, renal arterial disease, calculus disease) or the presence of systemic diseases (eg, diabetes). NSS in the solitary kidney is a challenging procedure, but good clinical outcomes can be achieved.

In a study from the Mayo Clinic, the 5- and 10-year overall and cancer-specific survival rates were 74.7% and 45.8% and 80.7% and 63.7%, respectively. [1] Interestingly, recurrence-free and metastasis-free survival rates were 89.2% and 80.3% and 69% and 50.4% at 5 and 10 years, respectively. Tumor stage and grade were significant predictors of death of any cause in this group of patients.

NSS is also indicated for RCC in patients with a normal contralateral renal unit, especially in younger patients with an incidental, localized, single, small (< 4 cm) RCC. Approximately 10-15% of small (< 3 cm) solid renal tumors are oncocytomas. A study from the Mayo Clinic of 106 renal masses treated with surgical resection revealed that 14% were benign (10% were oncocytomas). [2] When considering tumors smaller than 4 cm, the incidence of benign tumors increased to 22%, 18% of which were oncocytomas. Considering these factors, NSS would prevent unwarranted removal of a kidney for a benign lesion.

Recently, the indications for NSS have expanded to include all T1 lesions (1997 TNM staging system, up to 7 cm), even in the setting of a normal contralateral kidney. [3] Patients have to be appropriately selected and counseled, but recent data from UCLA support this approach. [3] When comparing T1 lesions under the previous 1987 staging system, in which T1 tumors were smaller than 4 cm with T1 lesions under the 1997 system, in which T1 tumors include lesions as large as 7 cm, no difference in survival was noted.

Other indications for NSS include hereditary papillary RCC and RCC associated with von Hippel-Lindau (VHL) syndrome. These syndromes are associated with multiple, multifocal renal lesions that cover the whole spectrum—from cysts to cystic renal neoplasms to solid renal neoplasms. These tumors are generally detected at an earlier stage than conventional sporadic RCC and are generally treated with NSS. Because of the relatively low metastatic potential of small renal masses, lesions smaller than 3 cm are generally monitored with careful surveillance to delay the onset of dialysis. When the lesion approaches or exceeds 3 cm, NSS is advocated when amenable to delay the onset of end-stage renal disease.

In addition to size, the location of the lesion in the kidney is an important criterion when considering NSS. Centrally located tumors near the hilum and adjacent to the collecting system are technically more difficult to remove than exophytic peripheral lesions. A recent study revealed that treatment with NSS or radical nephrectomy is equally effective, regardless of tumor location. No differences in 5-year cancer-specific (100% vs 97%) tumor recurrence rates (5.7% vs 4.5%) or postoperative renal function or complications exist between centrally or peripherally located tumors, respectively.

The value of NSS is realized further when one considers the unreliability of current imaging studies in distinguishing between malignant and benign tumors of the kidney. The most clinically relevant scenario is that of a small Bosniak category III lesion that does not meet the criteria of a clearly malignant or benign lesion. Simply stated, the Bosniak classification system divides renal cystic lesions into 4 categories based on CT scan criteria: I, simple cysts; II, mildly complicated but clearly benign cysts; III, more complicated cysts that need histologic confirmation for diagnosis; and IV, cystic neoplasms. Renal exploration and NSS are indicated and are the ideal form of treatment. Radical nephrectomy in this setting is excessive in the modern era.

Not all renal lesions are easily classified by the Bosniak system. Category I and IV lesions are relatively easy to designate because the former is a simple cyst and the latter is a cystic renal neoplasm with clearly solid enhancing regions. These lesions are usually diagnosed with a large degree of accuracy and confidence.

The main problem is in differentiating some complicated category II lesions from category III lesions. Category II lesions are predominantly cysts with 1 or 2 septae, perhaps with thin, smooth, and small calcifications in the wall or septum. As the number of septae and irregularities in the calcifications increase, the lesion approaches a category III designation. Category III lesions have increased and thick calcifications and septae with enhancing walls or septae. These require exploration because 50% are malignant. Some category II lesions that are clearly cystic and have some worrisome features (but not enough to categorize them as a Bosniak III lesions [eg, 3 or 4 septae with some calcification but no enhancement]) can be designated as Bosniak IIF and monitored with CT scans every 6 months and then every 12 months to establish their behavior.

Partial nephrectomy is the treatment of choice for certain benign conditions and localized pathology of the kidney. These include traumatic irreversible injury to a localized portion of the kidney and removal of a benign renal tumor such as an oncocytoma, angiomyolipoma, or multilocular cyst. Other indications include an obstructed atrophied segment of a duplicated kidney, calculous disease of a renal segment with impaired drainage, and, rarely, renovascular hypertension with identifiable noncorrectible branch renal artery disease.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!